

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1509)

RESUMPTION GUIDANCE

Reference is made to the announcement of Harmonicare Medical Holdings Limited (the “**Company**”) dated 1 April 2019 in respect of the suspension of trading (the “**Suspension**”) of its shares (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the two announcements of the Company dated 28 March 2019 and 7 May 2019 in relation to the background leading to the Suspension and the appointment of BDO Financial Services Limited as the Company’s independent internal control consultant. Capitalized terms used herein shall have the same meanings as defined in the announcement of the Company dated 28 March 2019 unless otherwise stated herein.

RESUMPTION GUIDANCE

On 15 May 2019, the Company received a letter from the Stock Exchange, in which the Stock Exchange stated the following resumption guidance for the Company:

- (a) publish all outstanding financial results and address any audit modifications;
- (b) conduct an independent internal control review and demonstrate that the Company has in place adequate internal control and procedures to comply with the Listing Rules; and
- (c) announce all material information for the Company’s shareholders and other investors to appraise the Company’s position.

The Stock Exchange may modify the resumption guidance which they may modify or supplement if the Company’s circumstances change.

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the Company's listing if trading in the Shares has remained suspended for 18 continuous months which expires on 30 September 2020. If the Company fails to remedy the issues causing the Suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in the Shares by 30 September 2020, the Listing Department of the Stock Exchange will recommend the Listing Committee to proceed with the cancellation of the Company's listing, subject to the Stock Exchange's right to impose a shorter specific remedial period under Rule 6.10 of the Listing Rules where appropriate.

The Company is taking appropriate steps to resolve the issues causing its Suspension and will seek to resume trading in the Shares as soon as possible. The Company will keep the Shareholders and the public informed of the latest developments by making further announcement(s) as and when appropriate.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2019. Trading in the Shares will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Harmonicare Medical Holdings Limited
Lin Yuming
Chairman, Executive Director and President

Hong Kong, 12 June 2019

As at the date of this announcement, the executive Directors of the Company are Mr. Lin Yuming, Mr. Fang Zhifeng and Mr. Zhao Xingli; the non-executive Directors of the Company are Mr. Lin Yuguo, Mr. Qiu Jianwei and Mr. Xu Jun; and the independent non-executive Directors of the Company are Mr. Kong Aiguo, Ms. Fang Lan and Mr. Cai Jiangnan.